Triple listing sank Beigene stock but this one is a true gem... - Printable Version

+- SG Talk (https://sgtalk.net)
+-- Forum: SG Talk (https://sgtalk.net/Forum-SG-Talk)
+--- Forum: Market Talk (https://sgtalk.net/Forum-Market-Talk)
+--- Thread: Triple listing sank Beigene stock but this one is a true gem... (/Thread-Triple-listing-sank-Beigene-stock-but-this-one-is-a-true-gem)

---

Triple listing sank Beigene stock but this one is a true gem... - sgbuffett - 14-02-2022

The stock started tanking after its 3rd listing which was in Shanghai ...after already being listed in US and Hong Kong.

The Shanghai listing has a few problems ..one is the China based investors are not familiar with biotech business model hence gave it a low valuation. The move to Shanghai also caused investors to fear the regulatory wreck will hit biotech firm and Beigene has to delist and shift back to China.

All these resulted in the stock getting hit and its true prospects forgotten in the selloff.

It's pipeline of cancer drugs is extremely strong and their science is validated by a number of FDA approvals.

This stocks has strong potential to be a multi bagger given its strengths.

Current stock price $122

---

RE: Triple listing sank Beigene stock but this one is a true gem... - sgbuffett - 14-02-2022

This company is a leader in its field and the deep expertise in the domain cannot be acquire easily. That is why major drug companies license its products.

---

RE: Triple listing sank Beigene stock but this one is a true gem... - sgbuffett - 14-02-2022

Beigene early pipeline:


https://www.beigene.com/science-and-product-portfolio/pipeline

---

RE: Triple listing sank Beigene stock but this one is a true gem... - sgbuffett - 25-02-2022

---

RE: Triple listing sank Beigene stock but this one is a true gem... - Zannn - 25-02-2022

(25-02-2022, 11:49 AM)sgbuffett Wrote:  

Old news

---

RE: Triple listing sank Beigene stock but this one is a true gem... - Zannn - 12-05-2022

(14-02-2022, 11:48 AM)sgbuffett Wrote:  The stock started tanking after its 3rd listing which was in Shanghai ...after already being listed in US and Hong Kong.

The Shanghai listing has a few problems ..one is the China based investors are not familiar with biotech business model hence gave it a low valuation. The move to Shanghai also caused investors to fear the regulatory wreck will hit biotech firm and Beigene has to delist and shift back to China.

All these resulted in the stock getting hit and its true prospects forgotten in the selloff.

It's pipeline of cancer drugs is extremely strong and their science is validated by a number of FDA approvals.

This stocks has strong potential to be a multi bagger given its strengths.

Current stock price $122

This one multi tanker scary. Hope u cut dude

---